Randall Schatzman, Bolt CEO

Bolt throws a wrench in the pipeline, look­ing to con­serve cash

A melt­down in the biotech mar­ket is mak­ing most ex­ecs cau­tious, in­clud­ing Bolt Bio­ther­a­peu­tics’ CEO, as the com­pa­ny hits the brakes on one pre­clin­i­cal as­set and paus­es oth­er ear­ly-stage work to ex­tend cash re­serves by two years.

The pipeline re-org will keep Bolt’s lights on through 2025 so the biotech can fo­cus on its clin­i­cal-stage HER2 sol­id tu­mor drug can­di­date, which the com­pa­ny should have ear­ly-stage da­ta on and a rec­om­mend­ed Phase II dose by year’s end. The biotech al­so wants to fo­cus on its pre­clin­i­cal as­set BDC-3042,  for KRAS and TP53 mu­tat­ed tu­mors.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters